Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects

Multicenter, Phase I, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Ascending Doses of Subcutaneous MSB0010841 (Anti-IL17A/F Nanobody) in Male and Female Subjects With Moderate to Severe Psoriasis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02156466

Enrollment

Registered

2014-06-05

Start date

2014-08-31

Completion date

2015-08-31

Last updated

2017-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Keywords

Psoriasis, MSB0010841, Anti-IL17A/F Nanobody, M1095

Brief summary

This is a multicenter, Phase 1, randomized, double-blind, placebo-controlled trial in subjects with moderate to severe psoriasis to assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of multiple subcutaneous ascending doses of MSB0010841 (Anti-interleukin-17A/F \[Anti-IL-17A/F\] Nanobody).

Interventions

DRUGMSB0010841

MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.

DRUGPlacebo

Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Chronic plaque psoriasis for at least 6 months before screening * Greater than or equal to (\>=) 10% of BSA with plaques * Psoriasis Area and Severity Index (PASI) \>=12 * Static Physician's Global Assessment (sPGA) \>=3 (where scores range from 0 \[clear of disease\] to 5 \[severe disease\]) at the screening and baseline visits * Other protocol defined inclusion criteria could apply

Exclusion criteria

* Any condition, including protocol-specified laboratory findings and findings in the medical history or in the pre-trial assessments which in the Investigator's opinion constitutes a risk or a contraindication for the subject's participation in the trial or that could interfere with the trial objectives, conduct or evaluation * Currently having a form of non-plaque psoriasis as specified in the protocol * Drug induced psoriasis * Biological treatments as specified in the protocol, within 3 months prior to Day 1 * Systemic immunosuppressants or phototherapy as specified in the protocol, within 1 month prior to Day 1 * Use of anti-coagulant medications and/or antiplatelet medications as defined in the protocol * Use of aspirin as defined in the protocol * Topical corticosteroid treatments other than low-strength or lower-mid strength corticosteroids on the face, scalp, axillae, and/or groin within 1 month prior to Day 1 * Any previous treatment with an agent targeting interleukin (IL)-17, IL-12 and/or IL-23 as specified in the protocol * Other protocol defined

Design outcomes

Primary

Measure	Time frame	Description
Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841	Pre-dose (0 hours) on Day 15	The observed serum concentration immediately before second dose.
Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)	The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100
Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100
Accumulation Ratio of Cmax (Racc (Cmax))	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	Accumulation ratio for Cmax was calculated as Cmax, after third dose / Cmax, after first dose.
Accumulation Ratio of AUC (Racc(AUC))	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	Accumulation ratio for AUC, calculated as area under the serum concentration-time curve within one complete dosing interval at third dose divided by area under the serum concentration-time curve within one complete dosing interval at first dose.
Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841	0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)	—
Number of Subjects With Treatment Emergent Adverse Events (TEAEs)	Baseline up to Day 85	An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were the AEs occurring or worsening after treatment administration.
Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1, 2,8, 15, 16, 22, 29, 30, 36, 43	The injection site was assessed by the Principal Investigator (PI) or his/her designee for local reactions such as redness, swelling, indurations or bruising, and by the subject for itching. Redness and bruising were scaled as None (no visible redness or bruising present); Mild (less than or equal to \[\<=\] 2.0 centimeters \[cm\] redness or bruising area); Moderate (greater than \[\>\] 2 to \<=5.0 cm redness or bruising area); Severe (\>5.0 cm redness or bruising area). Swelling was scaled as None (no swelling detected); Mild (palpable 'firmness' only); Moderate (\<= 4 cm swelling); Severe (\>4 cm swelling). Induration was scaled as None (no induration); Mild (able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up); Moderate (able to slide skin, unable to pinch skin); Severe (unable to slide or pinch skin). Itching was scaled as No itching; Mild itching; Moderate itching and Severe itching. Subjects who reported any of the local ISRs were reported.
Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 1, 2, 8, 15, 16, 22, 29, 30, 36, 43	Subjects were asked to assess their severity of injection site pain on a 100 millimeter (mm) VAS, where 0 = no pain and 100 = worst possible pain. Mean of amount of pain was calculated for the subjects having a value \> 0. Maximum values per subjects (over injection site areas) are used for counting the amount of pain at injection site. Maximum pain scores recorded among all participants analysed in each arm are reported for each time point.
Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])	Baseline up to Day 85	Data were presented for MSB0010841 combined group and placebo.
Levels of Anti-MSB0010841 Antibody Titers	Day 8, 15 (pre-dose), 22, 29 (pre-dose), 36, 43, 63 and 85	—
Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Pre-dose on Day 1	—
MSB0010841 Serum Concentration Over Time After First Dose	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)	—
MSB0010841 Serum Concentration Over Time After Second Dose	0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)	—
MSB0010841 Serum Concentration Over Time After Third Dose	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	—
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)	Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above lower limit of quantification (LLOQ).
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above LLOQ.
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)	Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)	Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	Area under the serum concentration-time curve from time zero to infinity (AUC0-inf). AUC0-infcalculated as AUC0-t + AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clast calc/λz, where Clast calc is the calculated concentration at the last sampling time point at which the measured concentration is at or above LLOQ and λz is the terminal rate constant determined from the terminal slope of the log transformed concentration curve using linear regression on terminal data points of the curve.
Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841	Pre-dose (0 hours) on Day 1	The observed serum concentration immediately before the first dose.
Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841	Pre-dose (0 hours) on Day 29	The observed serum concentration immediately before the third dose.
Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)	The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.
Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.
Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)	—
Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	—
Average Concentration (Cav) Post First Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)	Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).
Average Concentration (Cav) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).
Mean Residence Time (MRT0-t) Post First Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)	MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).
Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)	MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).
Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	Mean residence time of drug in the body from time zero extrapolated to infinity, based on the last predicted concentration at tlast.
Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)	—
Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841	0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)	—
Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	—
Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) multiplied by (\*) 2/ λz, where 'λz' is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Terminal Rate Constant (λz) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	Terminal rate constant was determined from the terminal slope of the logtransformed concentration curve using linear regression on terminal data points of the curve
Apparent Clearance (CL/f) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.
Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841	0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)	Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by elimination rate constant \[λz\]) following first dose and Dose/(AUCtau multiplied by λz) after third dose.

Secondary

Measure	Time frame	Description
Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43	Baseline, Day 43	PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of subjects who achieved \>=50 or 75% improvement in PASI score from Baseline.
Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 8, 15, 22, 29, 36, 43, 50, 85	The static Physician's Global Assessment (sPGA) scale rated the investigator's overall clinical assessment of a subjects plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Overall sPGA score ranged from 0 to 5, where lower scores indicate clinical improvement. Percentage of subjects who achieved a sPGA rating of 0 (clear) or 1 (minimal) and had at Least 2 level reduction from Baseline score were reported.
Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Baseline, Day 8, 15, 22, 29, 36, 43, 50 and 85	The BSA is the physician's evaluation for the extent of disease. The entire body area is divided into 4 districts: head, upper limbs, trunk and lower limbs to which corresponds the 10%, 20%, 30% and 40% of the entire body surface respectively. The investigator assesses the percentage of the subjects' body surface area affected by psoriasis in each district. The final affected BSA value is the sum of the percentage of each district.
Percentage of Subjects With Exacerbation of Psoriasis	Baseline up to Day 85	Psoriasis exacerbation was defined as either a worsening of 25% over the baseline value of the PASI score (PASI score at any visit \>=125% of baseline PASI).
Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score	Baseline up to Day 85	PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of participants who achieved \>=50 or 75% improvement in PASI score from Baseline.

Countries

Germany

Participant flow

Pre-assignment details

A total of 41 subjects were randomized in the trial and included in the Safety analysis set.

Participants by arm

Arm	Count
MSB0010841 30 mg MSB0010841 (Anti- IL-17A/F Nanobody) was administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.	8
MSB0010841 60 mg MSB0010841 was administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.	8
MSB0010841 120 mg MSB0010841 was administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.	8
MSB0010841 240 mg MSB0010841 was administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.	9
Placebo Placebo matched to MSB0010841 was administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.	8
Total	41

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004
Overall Study	Adverse Event	0	0	1	1	0
Overall Study	Quantiferon Positivity	0	0	0	1	0

Baseline characteristics

Characteristic	MSB0010841 30 mg	MSB0010841 240 mg	MSB0010841 60 mg	MSB0010841 120 mg	Placebo	Total
Age, Continuous	48.6 years STANDARD_DEVIATION 13.24	44.8 years STANDARD_DEVIATION 15.65	42.1 years STANDARD_DEVIATION 19.57	43.8 years STANDARD_DEVIATION 13.59	46.1 years STANDARD_DEVIATION 14.57	45.1 years STANDARD_DEVIATION 14.87
Gender Female	1 Participants	1 Participants	0 Participants	2 Participants	2 Participants	6 Participants
Gender Male	7 Participants	8 Participants	8 Participants	6 Participants	6 Participants	35 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	5 / 8	5 / 8	5 / 8	6 / 9	6 / 8
serious Total, serious adverse events	1 / 8	0 / 8	0 / 8	0 / 9	0 / 8

Outcome results

Primary

Accumulation Ratio of AUC (Racc(AUC))

Accumulation ratio for AUC, calculated as area under the serum concentration-time curve within one complete dosing interval at third dose divided by area under the serum concentration-time curve within one complete dosing interval at first dose.

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1) and 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Population: PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here Number of participants analyzed signifies those subjects who were evaluable for this outcome measure.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Accumulation Ratio of AUC (Racc(AUC))	1.61 ratio	Geometric Coefficient of Variation 15.9
MSB0010841 60 mg	Accumulation Ratio of AUC (Racc(AUC))	1.50 ratio	Geometric Coefficient of Variation 18.4
MSB0010841 120 mg	Accumulation Ratio of AUC (Racc(AUC))	1.61 ratio	Geometric Coefficient of Variation 27.4
MSB0010841 240 mg	Accumulation Ratio of AUC (Racc(AUC))	1.83 ratio	Geometric Coefficient of Variation 11.5

Primary

Accumulation Ratio of Cmax (Racc (Cmax))

Accumulation ratio for Cmax was calculated as Cmax, after third dose / Cmax, after first dose.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Accumulation Ratio of Cmax (Racc (Cmax))	1.56 ratio	Geometric Coefficient of Variation 17.9
MSB0010841 60 mg	Accumulation Ratio of Cmax (Racc (Cmax))	1.52 ratio	Geometric Coefficient of Variation 23.5
MSB0010841 120 mg	Accumulation Ratio of Cmax (Racc (Cmax))	1.56 ratio	Geometric Coefficient of Variation 34.1
MSB0010841 240 mg	Accumulation Ratio of Cmax (Racc (Cmax))	1.81 ratio	Geometric Coefficient of Variation 9.5

Primary

Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)

Subjects were asked to assess their severity of injection site pain on a 100 millimeter (mm) VAS, where 0 = no pain and 100 = worst possible pain. Mean of amount of pain was calculated for the subjects having a value \> 0. Maximum values per subjects (over injection site areas) are used for counting the amount of pain at injection site. Maximum pain scores recorded among all participants analysed in each arm are reported for each time point.

Time frame: Day 1, 2, 8, 15, 16, 22, 29, 30, 36, 43

Population: Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo). Here Number of subjects analyzed signifies those subjects who were evaluable for this endpoint and n signifies those subjects who were evaluable at the specified time point.

Arm	Measure	Group	Value (NUMBER)
MSB0010841 30 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 43 (n=0,0,0,0,0)	NA mm
MSB0010841 30 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 1 (n=3,2,3,2,0)	7 mm
MSB0010841 30 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 15 (n=2,1,3,0,0)	5 mm
MSB0010841 30 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 16 (n=0,0,0,0,2)	NA mm
MSB0010841 30 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 22 (1,0,1,0,0)	11 mm
MSB0010841 30 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 8 (n=1,1,0,0,0)	1 mm
MSB0010841 30 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 29 (n=1,1,1,0,0)	3 mm
MSB0010841 30 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 36 (n=0,0,0,0,0)	NA mm
MSB0010841 30 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 30 (1,0,1,1,0)	2 mm
MSB0010841 30 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 2 (n=1,1,1,1,0)	1 mm
MSB0010841 60 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 2 (n=1,1,1,1,0)	1 mm
MSB0010841 60 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 43 (n=0,0,0,0,0)	NA mm
MSB0010841 60 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 29 (n=1,1,1,0,0)	2 mm
MSB0010841 60 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 8 (n=1,1,0,0,0)	1 mm
MSB0010841 60 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 1 (n=3,2,3,2,0)	4 mm
MSB0010841 60 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 15 (n=2,1,3,0,0)	3 mm
MSB0010841 60 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 22 (1,0,1,0,0)	NA mm
MSB0010841 60 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 36 (n=0,0,0,0,0)	NA mm
MSB0010841 60 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 16 (n=0,0,0,0,2)	NA mm
MSB0010841 60 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 30 (1,0,1,1,0)	NA mm
MSB0010841 120 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 30 (1,0,1,1,0)	1 mm
MSB0010841 120 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 16 (n=0,0,0,0,2)	NA mm
MSB0010841 120 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 36 (n=0,0,0,0,0)	NA mm
MSB0010841 120 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 43 (n=0,0,0,0,0)	NA mm
MSB0010841 120 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 2 (n=1,1,1,1,0)	1 mm
MSB0010841 120 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 1 (n=3,2,3,2,0)	7 mm
MSB0010841 120 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 8 (n=1,1,0,0,0)	NA mm
MSB0010841 120 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 15 (n=2,1,3,0,0)	7 mm
MSB0010841 120 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 22 (1,0,1,0,0)	1 mm
MSB0010841 120 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 29 (n=1,1,1,0,0)	2 mm
MSB0010841 240 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 1 (n=3,2,3,2,0)	4 mm
MSB0010841 240 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 30 (1,0,1,1,0)	1 mm
MSB0010841 240 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 2 (n=1,1,1,1,0)	1 mm
MSB0010841 240 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 8 (n=1,1,0,0,0)	NA mm
MSB0010841 240 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 15 (n=2,1,3,0,0)	NA mm
MSB0010841 240 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 16 (n=0,0,0,0,2)	NA mm
MSB0010841 240 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 22 (1,0,1,0,0)	NA mm
MSB0010841 240 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 43 (n=0,0,0,0,0)	NA mm
MSB0010841 240 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 29 (n=1,1,1,0,0)	NA mm
MSB0010841 240 mg	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 36 (n=0,0,0,0,0)	NA mm
Placebo	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 36 (n=0,0,0,0,0)	NA mm
Placebo	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 15 (n=2,1,3,0,0)	NA mm
Placebo	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 2 (n=1,1,1,1,0)	NA mm
Placebo	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 30 (1,0,1,1,0)	NA mm
Placebo	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 22 (1,0,1,0,0)	NA mm
Placebo	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 29 (n=1,1,1,0,0)	NA mm
Placebo	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 8 (n=1,1,0,0,0)	NA mm
Placebo	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 43 (n=0,0,0,0,0)	NA mm
Placebo	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 1 (n=3,2,3,2,0)	NA mm
Placebo	Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)	Day 16 (n=0,0,0,0,2)	2 mm

Primary

Apparent Clearance (CL/f) Post Third Dose of MSB0010841

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Apparent Clearance (CL/f) Post Third Dose of MSB0010841	0.55 L/day	Geometric Coefficient of Variation 36.3
MSB0010841 60 mg	Apparent Clearance (CL/f) Post Third Dose of MSB0010841	0.58 L/day	Geometric Coefficient of Variation 33.9
MSB0010841 120 mg	Apparent Clearance (CL/f) Post Third Dose of MSB0010841	0.59 L/day	Geometric Coefficient of Variation 43.6
MSB0010841 240 mg	Apparent Clearance (CL/f) Post Third Dose of MSB0010841	0.60 L/day	Geometric Coefficient of Variation 27.1

Primary

Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) multiplied by (\*) 2/ λz, where 'λz' is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841	10.63 day	Geometric Coefficient of Variation 17.3
MSB0010841 60 mg	Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841	10.50 day	Geometric Coefficient of Variation 18.9
MSB0010841 120 mg	Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841	12.19 day	Geometric Coefficient of Variation 27.9
MSB0010841 240 mg	Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841	10.25 day	Geometric Coefficient of Variation 13.1

Primary

Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by elimination rate constant \[λz\]) following first dose and Dose/(AUCtau multiplied by λz) after third dose.

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Population: PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here Number of subjects analyzed signifies those subjects who were evaluable for this outcome measure.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841	8.49 Liters	Geometric Coefficient of Variation 27
MSB0010841 60 mg	Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841	8.73 Liters	Geometric Coefficient of Variation 38.6
MSB0010841 120 mg	Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841	10.39 Liters	Geometric Coefficient of Variation 21.9
MSB0010841 240 mg	Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841	8.92 Liters	Geometric Coefficient of Variation 18.8

Primary

Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841

Area under the serum concentration-time curve from time zero to infinity (AUC0-inf). AUC0-infcalculated as AUC0-t + AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clast calc/λz, where Clast calc is the calculated concentration at the last sampling time point at which the measured concentration is at or above LLOQ and λz is the terminal rate constant determined from the terminal slope of the log transformed concentration curve using linear regression on terminal data points of the curve.

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841	97.6 day*ug/mL	Geometric Coefficient of Variation 42.2
MSB0010841 60 mg	Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841	174.9 day*ug/mL	Geometric Coefficient of Variation 39.9
MSB0010841 120 mg	Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841	392.6 day*ug/mL	Geometric Coefficient of Variation 68.8
MSB0010841 240 mg	Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841	680.9 day*ug/mL	Geometric Coefficient of Variation 32.2

Primary

Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841

Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841	32.4 day*mcg/mL	Geometric Coefficient of Variation 31.2
MSB0010841 60 mg	Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841	68.3 day*mcg/mL	Geometric Coefficient of Variation 16.4
MSB0010841 120 mg	Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841	114.6 day*mcg/mL	Geometric Coefficient of Variation 24.2
MSB0010841 240 mg	Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841	222.2 day*mcg/mL	Geometric Coefficient of Variation 19.6

Primary

Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841

Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841	54.2 day*mcg/mL	Geometric Coefficient of Variation 36.3
MSB0010841 60 mg	Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841	104.1 day*mcg/mL	Geometric Coefficient of Variation 33.9
MSB0010841 120 mg	Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841	203.2 day*mcg/mL	Geometric Coefficient of Variation 43.6
MSB0010841 240 mg	Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841	397.6 day*mcg/mL	Geometric Coefficient of Variation 27.1

Primary

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841

Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above lower limit of quantification (LLOQ).

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841	33.6 daymicrogram per milliliter (daymcg/mL	Geometric Coefficient of Variation 28
MSB0010841 60 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841	69.3 daymicrogram per milliliter (daymcg/mL	Geometric Coefficient of Variation 18.9
MSB0010841 120 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841	126.3 daymicrogram per milliliter (daymcg/mL	Geometric Coefficient of Variation 28.5
MSB0010841 240 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841	216.5 daymicrogram per milliliter (daymcg/mL	Geometric Coefficient of Variation 23.4

Primary

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841

Area under the serum concentration-time curve (AUC) from time zero to the last sampling time point at which the concentration is at or above LLOQ.

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841	93.7 day*mcg/mL	Geometric Coefficient of Variation 41.4
MSB0010841 60 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841	170.3 day*mcg/mL	Geometric Coefficient of Variation 39.5
MSB0010841 120 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841	371.7 day*mcg/mL	Geometric Coefficient of Variation 62
MSB0010841 240 mg	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841	663.4 day*mcg/mL	Geometric Coefficient of Variation 31.1

Primary

Average Concentration (Cav) Post First Dose of MSB0010841

Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Average Concentration (Cav) Post First Dose of MSB0010841	2.315 mcg/mL	Geometric Coefficient of Variation 31.2
MSB0010841 60 mg	Average Concentration (Cav) Post First Dose of MSB0010841	4.881 mcg/mL	Geometric Coefficient of Variation 16.4
MSB0010841 120 mg	Average Concentration (Cav) Post First Dose of MSB0010841	8.187 mcg/mL	Geometric Coefficient of Variation 24.2
MSB0010841 240 mg	Average Concentration (Cav) Post First Dose of MSB0010841	15.868 mcg/mL	Geometric Coefficient of Variation 19.6

Primary

Average Concentration (Cav) Post Third Dose of MSB0010841

Cav was calculated by AUCtau/tau. Where tau is the dosing interval (336 hours).

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Average Concentration (Cav) Post Third Dose of MSB0010841	3.87 mcg/mL	Geometric Coefficient of Variation 36.3
MSB0010841 60 mg	Average Concentration (Cav) Post Third Dose of MSB0010841	7.44 mcg/mL	Geometric Coefficient of Variation 33.9
MSB0010841 120 mg	Average Concentration (Cav) Post Third Dose of MSB0010841	14.51 mcg/mL	Geometric Coefficient of Variation 43.6
MSB0010841 240 mg	Average Concentration (Cav) Post Third Dose of MSB0010841	28.40 mcg/mL	Geometric Coefficient of Variation 27.1

Primary

Levels of Anti-MSB0010841 Antibody Titers

Time frame: Day 8, 15 (pre-dose), 22, 29 (pre-dose), 36, 43, 63 and 85

Population: All subjects who received placebo or MSB0010841 (30 mg, 60 mg, 90 mg or 240 mg) and had positive ADA titers before and/or after study drug administration were included in the analysis population.

Arm	Measure	Group	Value (NUMBER)
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 11: MSB0010841 120 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 12: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 13: MSB0010841 240 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 1: Placebo	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 2: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 8: MSB0010841 120 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 9: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 10: MSB0010841 120 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 11: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 1: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 2: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 3: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 4: MSB0010841 30 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 5: MSB0010841 30 mg	0 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 6: MSB0010841 30 mg	2.28 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 7: MSB0010841 60 mg	0 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 8: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 9: MSB0010841 120 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 10: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 11: MSB0010841 120 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 12: MSB0010841 120 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 8 Subject 13: MSB0010841 240 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 1: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 2: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 3: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 4: MSB0010841 30 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 5: MSB0010841 30 mg	0 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 6: MSB0010841 30 mg	2.28 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 7: MSB0010841 60 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 8: MSB0010841 120 mg	5.78 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 9: MSB0010841 120 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 10: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 11: MSB0010841 120 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 12: MSB0010841 120 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 15 (pre-dose) Subject 13: MSB0010841 240 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 1: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 2: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 3: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 4: MSB0010841 30 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 5: MSB0010841 30 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 6: MSB0010841 30 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 7: MSB0010841 60 mg	2.28 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 8: MSB0010841 120 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 9: MSB0010841 120 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 10: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 11: MSB0010841 120 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 12: MSB0010841 120 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 22 Subject 13: MSB0010841 240 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 1: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 2: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 3: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 4: MSB0010841 30 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 5: MSB0010841 30 mg	0 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 6: MSB0010841 30 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 7: MSB0010841 60 mg	2.28 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 8: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 9: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 10: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 11: MSB0010841 120 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 12: MSB0010841 120 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 29 (pre-dose) Subject 13: MSB0010841 240 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 1: Placebo	NA log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 2: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 3: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 4: MSB0010841 30 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 5: MSB0010841 30 mg	0 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 6: MSB0010841 30 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 7: MSB0010841 60 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 8: MSB0010841 120 mg	NA log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 9: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 36 Subject 10: MSB0010841 120 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 3: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 4: MSB0010841 30 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 5: MSB0010841 30 mg	0 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 6: MSB0010841 30 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 7: MSB0010841 60 mg	2.28 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 12: MSB0010841 120 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 43 Subject 13: MSB0010841 240 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 1: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 2: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 3: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 4: MSB0010841 30 mg	4.38 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 5: MSB0010841 30 mg	0 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 6: MSB0010841 30 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 7: MSB0010841 60 mg	2.28 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 8: MSB0010841 120 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 9: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 10: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 11: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 12: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 63 Subject 13: MSB0010841 240 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 1: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 2: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 3: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 4: MSB0010841 30 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 5: MSB0010841 30 mg	0 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 6: MSB0010841 30 mg	2.28 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 7: MSB0010841 60 mg	2.28 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 8: MSB0010841 120 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 9: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 10: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 11: MSB0010841 120 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 12: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Anti-MSB0010841 Antibody Titers	Day 85 Subject 13: MSB0010841 240 mg	2.98 log10titer

Primary

Levels of Pre-existing Anti-MSB0010841 Antibody Titers

Time frame: Pre-dose on Day 1

Arm	Measure	Group	Value (NUMBER)
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 1: Placebo	2.98 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 2: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 3: Placebo	3.68 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 4: MSB0010841 30 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 5: MSB0010841 30 mg	0 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 6: MSB0010841 30 mg	0 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 7: MSB0010841 60 mg	0 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 8: MSB0010841 120 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 9: MSB0010841 120 mg	5.08 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 10: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 11: MSB0010841 120 mg	3.68 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 12: MSB0010841 120 mg	2.98 log10titer
MSB0010841 30 mg	Levels of Pre-existing Anti-MSB0010841 Antibody Titers	Subject 13: MSB0010841 240 mg	0 log10titer

Primary

Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841	3.3 mcg/mL	Geometric Coefficient of Variation 28.4
MSB0010841 60 mg	Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841	7.4 mcg/mL	Geometric Coefficient of Variation 22.9
MSB0010841 120 mg	Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841	12.5 mcg/mL	Geometric Coefficient of Variation 25.6
MSB0010841 240 mg	Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841	20.8 mcg/mL	Geometric Coefficient of Variation 30.3

Primary

Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841	5.14 mcg/mL	Geometric Coefficient of Variation 34.5
MSB0010841 60 mg	Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841	11.32 mcg/mL	Geometric Coefficient of Variation 29.7
MSB0010841 120 mg	Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841	19.74 mcg/mL	Geometric Coefficient of Variation 31.3
MSB0010841 240 mg	Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841	37.93 mcg/mL	Geometric Coefficient of Variation 32.2

Primary

Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841

Time frame: 0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)

Population: PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here Number of subjects analyzed signifies those subjects who were evaluable for this outcome measure.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841	4.26 mcg/mL	Geometric Coefficient of Variation 32.7
MSB0010841 60 mg	Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841	9.06 mcg/mL	Geometric Coefficient of Variation 24.2
MSB0010841 120 mg	Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841	18.59 mcg/mL	Geometric Coefficient of Variation 23.1
MSB0010841 240 mg	Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841	30.98 mcg/mL	Geometric Coefficient of Variation 25.3

Primary

Mean Residence Time (MRT0-t) Post First Dose of MSB0010841

MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(0-t)/AUC(0-t) where AUMC(0-t) is area under the plasma concentration-time first moment curve from time zero to time t (336 hours) and AUC(0-t) is the area under the plasma concentration-time curve from time zero to tome t (336 hours).

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Mean Residence Time (MRT0-t) Post First Dose of MSB0010841	6.528 day	Geometric Coefficient of Variation 3.6
MSB0010841 60 mg	Mean Residence Time (MRT0-t) Post First Dose of MSB0010841	6.691 day	Geometric Coefficient of Variation 8.1
MSB0010841 120 mg	Mean Residence Time (MRT0-t) Post First Dose of MSB0010841	6.638 day	Geometric Coefficient of Variation 5.7
MSB0010841 240 mg	Mean Residence Time (MRT0-t) Post First Dose of MSB0010841	6.771 day	Geometric Coefficient of Variation 5.3

Primary

Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-third dose (Day 29)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841	17.57 day	Geometric Coefficient of Variation 11.2
MSB0010841 60 mg	Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841	15.68 day	Geometric Coefficient of Variation 16.3
MSB0010841 120 mg	Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841	19.26 day	Geometric Coefficient of Variation 32
MSB0010841 240 mg	Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841	16.38 day	Geometric Coefficient of Variation 11.3

Primary

Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841

Mean residence time of drug in the body from time zero extrapolated to infinity, based on the last predicted concentration at tlast.

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841	17.57 day	Geometric Coefficient of Variation 11.2
MSB0010841 60 mg	Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841	15.68 day	Geometric Coefficient of Variation 16.3
MSB0010841 120 mg	Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841	19.26 day	Geometric Coefficient of Variation 32
MSB0010841 240 mg	Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841	16.38 day	Geometric Coefficient of Variation 11.3

Primary

Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841

The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

Arm	Measure	Value (MEAN)	Dispersion
MSB0010841 30 mg	Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841	0.01 mcg/mL	Standard Deviation 0.036
MSB0010841 60 mg	Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841	0.00 mcg/mL	Standard Deviation 0
MSB0010841 120 mg	Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841	0.00 mcg/mL	Standard Deviation 0
MSB0010841 240 mg	Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841	0.00 mcg/mL	Standard Deviation 0

Primary

Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841

The observed minimum serum concentration determined directly from the serum concentration-time profile of each subject.

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Arm	Measure	Value (MEAN)	Dispersion
MSB0010841 30 mg	Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841	2.30 mcg/mL	Standard Deviation 0.6
MSB0010841 60 mg	Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841	4.34 mcg/mL	Standard Deviation 1.4
MSB0010841 120 mg	Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841	10.03 mcg/mL	Standard Deviation 4.95
MSB0010841 240 mg	Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841	16.17 mcg/mL	Standard Deviation 4.84

Primary

MSB0010841 Serum Concentration Over Time After First Dose

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

Population: PK analysis set included subjects who received first dose of MSB0010841 without protocol deviations affecting PK, and who provide evaluable PK data. Here n signifies those subjects who were evaluable for this outcome measure at the specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After First Dose	96 hour (n=8,8,8,8)	3155.8 nanogram/milliliter (ng/mL)	Standard Deviation 879.56
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After First Dose	72 hour (n=8,8,7,8)	3190.4 nanogram/milliliter (ng/mL)	Standard Deviation 810.18
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After First Dose	336 hour (n=8,8,8,8)	1704.3 nanogram/milliliter (ng/mL)	Standard Deviation 429.78
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After First Dose	24 hour (n=8,8,8,9)	2788.4 nanogram/milliliter (ng/mL)	Standard Deviation 895.89
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After First Dose	12 hour (n=8,8,8,9)	1793.3 nanogram/milliliter (ng/mL)	Standard Deviation 761.23
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After First Dose	6 hour (n=8,8,8,9)	907.5 nanogram/milliliter (ng/mL)	Standard Deviation 523.16
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After First Dose	168 hour (n=8,8,8,8)	2665.5 nanogram/milliliter (ng/mL)	Standard Deviation 605.89
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After First Dose	32 hour (n=8,8,8,9)	3037.3 nanogram/milliliter (ng/mL)	Standard Deviation 820.76
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After First Dose	0 hour (n=8,8,8,9)	12.6 nanogram/milliliter (ng/mL)	Standard Deviation 35.71
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After First Dose	32 hour (n=8,8,8,9)	6028.1 nanogram/milliliter (ng/mL)	Standard Deviation 2269.66
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After First Dose	96 hour (n=8,8,8,8)	6423.8 nanogram/milliliter (ng/mL)	Standard Deviation 1824.46
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After First Dose	72 hour (n=8,8,7,8)	6492.9 nanogram/milliliter (ng/mL)	Standard Deviation 1472.29
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After First Dose	6 hour (n=8,8,8,9)	2097.1 nanogram/milliliter (ng/mL)	Standard Deviation 1391.43
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After First Dose	0 hour (n=8,8,8,9)	0.0 nanogram/milliliter (ng/mL)	Standard Deviation 0
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After First Dose	12 hour (n=8,8,8,9)	3339.6 nanogram/milliliter (ng/mL)	Standard Deviation 1671.29
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After First Dose	336 hour (n=8,8,8,8)	3951.0 nanogram/milliliter (ng/mL)	Standard Deviation 1353.92
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After First Dose	168 hour (n=8,8,8,8)	5179.5 nanogram/milliliter (ng/mL)	Standard Deviation 1126.74
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After First Dose	24 hour (n=8,8,8,9)	5047.8 nanogram/milliliter (ng/mL)	Standard Deviation 1600.25
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After First Dose	32 hour (n=8,8,8,9)	11372.4 nanogram/milliliter (ng/mL)	Standard Deviation 3499.37
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After First Dose	0 hour (n=8,8,8,9)	0.0 nanogram/milliliter (ng/mL)	Standard Deviation 0
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After First Dose	6 hour (n=8,8,8,9)	2315.5 nanogram/milliliter (ng/mL)	Standard Deviation 787.02
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After First Dose	12 hour (n=8,8,8,9)	4983.1 nanogram/milliliter (ng/mL)	Standard Deviation 1501.41
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After First Dose	24 hour (n=8,8,8,9)	9131.3 nanogram/milliliter (ng/mL)	Standard Deviation 2838.02
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After First Dose	72 hour (n=8,8,7,8)	11284.1 nanogram/milliliter (ng/mL)	Standard Deviation 2562.84
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After First Dose	96 hour (n=8,8,8,8)	11790.0 nanogram/milliliter (ng/mL)	Standard Deviation 3319.36
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After First Dose	168 hour (n=8,8,8,8)	10318.6 nanogram/milliliter (ng/mL)	Standard Deviation 2837.81
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After First Dose	336 hour (n=8,8,8,8)	6768.4 nanogram/milliliter (ng/mL)	Standard Deviation 2846.24
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After First Dose	96 hour (n=8,8,8,8)	18732.9 nanogram/milliliter (ng/mL)	Standard Deviation 4670.66
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After First Dose	24 hour (n=8,8,8,9)	15357.6 nanogram/milliliter (ng/mL)	Standard Deviation 5295.18
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After First Dose	12 hour (n=8,8,8,9)	9780.3 nanogram/milliliter (ng/mL)	Standard Deviation 4698.97
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After First Dose	336 hour (n=8,8,8,8)	11605.8 nanogram/milliliter (ng/mL)	Standard Deviation 2065.58
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After First Dose	168 hour (n=8,8,8,8)	17761.9 nanogram/milliliter (ng/mL)	Standard Deviation 3072.48
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After First Dose	6 hour (n=8,8,8,9)	4858.8 nanogram/milliliter (ng/mL)	Standard Deviation 2326.35
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After First Dose	72 hour (n=8,8,7,8)	20536.6 nanogram/milliliter (ng/mL)	Standard Deviation 6716.38
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After First Dose	32 hour (n=8,8,8,9)	17135.2 nanogram/milliliter (ng/mL)	Standard Deviation 6032.66
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After First Dose	0 hour (n=8,8,8,9)	0.0 nanogram/milliliter (ng/mL)	Standard Deviation 0

Primary

MSB0010841 Serum Concentration Over Time After Second Dose

Time frame: 0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)

Arm	Measure	Group	Value (MEAN)	Dispersion
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Second Dose	96 hour	4020.5 ng/mL	Standard Deviation 923.65
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Second Dose	0 hour	1704.3 ng/mL	Standard Deviation 429.78
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Second Dose	72 hour	4309.0 ng/mL	Standard Deviation 1265.45
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Second Dose	168 hour	3517.8 ng/mL	Standard Deviation 877.96
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Second Dose	336 hour	2306.5 ng/mL	Standard Deviation 588.5
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Second Dose	24 hour	3808.0 ng/mL	Standard Deviation 980.68
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Second Dose	336 hour	4492.9 ng/mL	Standard Deviation 1398.63
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Second Dose	168 hour	7180.4 ng/mL	Standard Deviation 1705.24
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Second Dose	0 hour	3951.0 ng/mL	Standard Deviation 1353.92
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Second Dose	96 hour	8514.4 ng/mL	Standard Deviation 1849.44
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Second Dose	72 hour	9095.5 ng/mL	Standard Deviation 2115.16
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Second Dose	24 hour	7268.9 ng/mL	Standard Deviation 3771.98
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Second Dose	168 hour	14806.6 ng/mL	Standard Deviation 5632.99
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Second Dose	96 hour	17081.4 ng/mL	Standard Deviation 5056.17
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Second Dose	336 hour	10468.9 ng/mL	Standard Deviation 4376.75
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Second Dose	0 hour	6768.4 ng/mL	Standard Deviation 2846.24
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Second Dose	24 hour	15120.6 ng/mL	Standard Deviation 3393.84
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Second Dose	72 hour	17454.4 ng/mL	Standard Deviation 4152.32
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Second Dose	168 hour	22972.5 ng/mL	Standard Deviation 11219.87
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Second Dose	72 hour	29902.4 ng/mL	Standard Deviation 7523.13
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Second Dose	24 hour	27664.8 ng/mL	Standard Deviation 9231.41
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Second Dose	96 hour	29223.5 ng/mL	Standard Deviation 8336.26
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Second Dose	0 hour	11605.8 ng/mL	Standard Deviation 2065.58
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Second Dose	336 hour	16454.5 ng/mL	Standard Deviation 4548.85

Primary

MSB0010841 Serum Concentration Over Time After Third Dose

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Arm	Measure	Group	Value (MEAN)	Dispersion
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	6 hour	3483.9 ng/mL	Standard Deviation 1566.88
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	32 hour	4934.5 ng/mL	Standard Deviation 1256.47
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	24 hour	4533.3 ng/mL	Standard Deviation 1178.14
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	816 hour	933.1 ng/mL	Standard Deviation 376.76
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	1344 hour	244.8 ng/mL	Standard Deviation 162.24
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	12 hour	3557.9 ng/mL	Standard Deviation 1004.43
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	168 hour	4368.1 ng/mL	Standard Deviation 1201.56
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	0 hour	2306.5 ng/mL	Standard Deviation 588.5
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	336 hour	2680.5 ng/mL	Standard Deviation 859.35
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	1056 hour	464.5 ng/mL	Standard Deviation 257.13
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	96 hour	4994.9 ng/mL	Standard Deviation 1448.53
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	72 hour	4936.0 ng/mL	Standard Deviation 1387.5
MSB0010841 30 mg	MSB0010841 Serum Concentration Over Time After Third Dose	504 hour	1802.0 ng/mL	Standard Deviation 505.42
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	96 hour	9047.6 ng/mL	Standard Deviation 2760.25
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	0 hour	4492.9 ng/mL	Standard Deviation 1398.63
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	6 hour	6200.1 ng/mL	Standard Deviation 1391.38
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	336 hour	5602.1 ng/mL	Standard Deviation 3057.34
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	504 hour	3109.1 ng/mL	Standard Deviation 1519.66
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	816 hour	1378.1 ng/mL	Standard Deviation 834.66
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	72 hour	10345.6 ng/mL	Standard Deviation 4586.24
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	12 hour	8615.5 ng/mL	Standard Deviation 3093.46
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	24 hour	9969.9 ng/mL	Standard Deviation 2494.6
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	32 hour	10762.5 ng/mL	Standard Deviation 2377.88
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	168 hour	7715.4 ng/mL	Standard Deviation 3019.93
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	1056 hour	658.5 ng/mL	Standard Deviation 391.39
MSB0010841 60 mg	MSB0010841 Serum Concentration Over Time After Third Dose	1344 hour	326.3 ng/mL	Standard Deviation 230.87
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	12 hour	13361.0 ng/mL	Standard Deviation 5959.26
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	24 hour	17523.1 ng/mL	Standard Deviation 6140.31
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	504 hour	8610.6 ng/mL	Standard Deviation 5991.68
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	0 hour	10417.7 ng/mL	Standard Deviation 4724.84
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	32 hour	18634.9 ng/mL	Standard Deviation 5713.14
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	72 hour	19813.1 ng/mL	Standard Deviation 6381.27
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	336 hour	12257.6 ng/mL	Standard Deviation 7468.85
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	168 hour	15585.3 ng/mL	Standard Deviation 5625.65
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	96 hour	18260.1 ng/mL	Standard Deviation 6602.9
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	1344 hour	1611.3 ng/mL	Standard Deviation 2199.92
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	6 hour	12725.0 ng/mL	Standard Deviation 5573.11
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	816 hour	4309.3 ng/mL	Standard Deviation 4044.88
MSB0010841 120 mg	MSB0010841 Serum Concentration Over Time After Third Dose	1056 hour	2599.7 ng/mL	Standard Deviation 2937.08
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	6 hour	20452.3 ng/mL	Standard Deviation 6683.19
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	504 hour	12472.4 ng/mL	Standard Deviation 4176
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	1056 hour	2475.9 ng/mL	Standard Deviation 1391.08
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	12 hour	26051.4 ng/mL	Standard Deviation 8770.65
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	24 hour	33651.7 ng/mL	Standard Deviation 11590.56
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	96 hour	33909.3 ng/mL	Standard Deviation 10219.54
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	168 hour	31375.9 ng/mL	Standard Deviation 6826.5
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	1344 hour	1345.7 ng/mL	Standard Deviation 879.15
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	32 hour	38278.4 ng/mL	Standard Deviation 13391.4
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	336 hour	20011.9 ng/mL	Standard Deviation 6248.98
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	0 hour	16173.6 ng/mL	Standard Deviation 4837.78
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	72 hour	37166.4 ng/mL	Standard Deviation 10103.58
MSB0010841 240 mg	MSB0010841 Serum Concentration Over Time After Third Dose	816 hour	5064.6 ng/mL	Standard Deviation 2070.93

Primary

Number of Subjects With Local Injection Site Reactions (ISRs)

The injection site was assessed by the Principal Investigator (PI) or his/her designee for local reactions such as redness, swelling, indurations or bruising, and by the subject for itching. Redness and bruising were scaled as None (no visible redness or bruising present); Mild (less than or equal to \[\<=\] 2.0 centimeters \[cm\] redness or bruising area); Moderate (greater than \[\>\] 2 to \<=5.0 cm redness or bruising area); Severe (\>5.0 cm redness or bruising area). Swelling was scaled as None (no swelling detected); Mild (palpable 'firmness' only); Moderate (\<= 4 cm swelling); Severe (\>4 cm swelling). Induration was scaled as None (no induration); Mild (able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up); Moderate (able to slide skin, unable to pinch skin); Severe (unable to slide or pinch skin). Itching was scaled as No itching; Mild itching; Moderate itching and Severe itching. Subjects who reported any of the local ISRs were reported.

Time frame: Day 1, 2,8, 15, 16, 22, 29, 30, 36, 43

Population: Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo). Here n signifies those subjects who were evaluable for the specified injection site reaction. Subjects may be represented in more than 1 category.

Arm	Measure	Group	Value (NUMBER)
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Redness: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Redness: none (n=8,8,8,9,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Itching: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Redness: none (n==8,8,7,7,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Bruising: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: moderate (n=8,8,8,8,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Redness: moderate (n=8,8,7,7,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Itching: none (n=7,8,7,6,8)	7 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Indurations: none (n=8,8,7,7,7)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Swelling: none (n=8,8,7,7,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Itching: none (n=8,8,8,7,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Bruising: mild (n=7,8,7,7,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Bruising: none (n=7,8,7,7,8)	7 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Redness: severe (n=8,8,8,8,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Bruising: none (n=8,8,8,7,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Swelling: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Itching: none (n=8,8,8,9,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Indurations: none (n=8,8,8,9,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Indurations: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Itching: mild (n=8,8,8,8,8)	1 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Bruising: none (n=8,8,8,9,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Redness: moderate (n=8,8,8,8,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Swelling: severe (n=8,8,8,8,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Redness: mild (n=8,8,8,8,8)	1 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Redness: none (n=8,8,8,8,8)	7 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: moderate (n=8,8,8,8,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Itching: none (n=8,8,8,8,8)	7 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Bruising: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Itching: none (8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Swelling: none (n=8,8,8,7,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Redness: mild (n=8,8,8,8,8)	1 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Swelling: mild (n=8,8,8,7,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Indurations: severe (n=8,8,8,8,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Redness: none (n=8,8,8,8,8)	7 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Bruising: none (n=8,8,8,7,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Indurations: none (n=8,8,7,7,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Swelling: none (n=8,8,8,9,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Redness: none (n=8,8,8,9,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Bruising: mild (n=8,8,8,7,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Itching: none (n=8,8,8,9,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Indurations: none (n=8,8,8,9,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Bruising: mild (n=8,8,8,9,8)	3 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Indurations: none (n=8,8,7,7,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Bruising: none (n=8,8,8,9,8)	5 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Swelling: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Swelling: none (n=8,8,8,9,8)	8 subjects
MSB0010841 30 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Itching: none (n=8,8,7,7,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Bruising: none (n=8,8,8,8,8)	7 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Bruising: none (n=8,8,8,7,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Indurations: none (n=8,8,7,7,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Itching: none (n=8,8,8,7,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: none (n=8,8,8,8,8)	7 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: mild (n=8,8,8,8,8)	1 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: moderate (n=8,8,8,8,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Swelling: none (n=8,8,8,7,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Swelling: mild (n=8,8,8,7,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Bruising: none (n=8,8,8,7,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Bruising: mild (n=8,8,8,7,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Indurations: none (n=8,8,7,7,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Itching: none (n=8,8,7,7,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Redness: none (n==8,8,7,7,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Redness: moderate (n=8,8,7,7,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Swelling: none (n=8,8,7,7,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Bruising: none (n=7,8,7,7,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Bruising: mild (n=7,8,7,7,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Indurations: none (n=8,8,7,7,7)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Itching: none (n=7,8,7,6,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: moderate (n=8,8,8,8,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Itching: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Redness: none (n=8,8,8,9,8)	7 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Redness: mild (n=8,8,8,9,8)	1 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Swelling: none (n=8,8,8,9,8)	7 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Swelling: mild (n=8,8,8,9,8)	1 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Bruising: none (n=8,8,8,9,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Bruising: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Indurations: none (n=8,8,8,9,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Itching: none (n=8,8,8,9,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Redness: none (n=8,8,8,9,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Swelling: none (n=8,8,8,9,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Redness: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Bruising: mild (n=8,8,8,8,8)	1 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Redness: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Itching: none (8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Redness: moderate (n=8,8,8,8,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Indurations: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Bruising: none (n=8,8,8,9,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Indurations: none (n=8,8,8,9,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Itching: none (n=8,8,8,9,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Swelling: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Bruising: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Indurations: severe (n=8,8,8,8,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Itching: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Redness: severe (n=8,8,8,8,8)	0 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 60 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Swelling: severe (n=8,8,8,8,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: moderate (n=8,8,8,8,8)	1 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Redness: none (n=8,8,8,8,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Swelling: none (n=8,8,8,7,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Indurations: mild (n=8,8,8,9,8)	1 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Itching: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Bruising: none (n=8,8,8,9,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Indurations: none (n=8,8,8,9,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Indurations: none (n=8,8,8,9,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: moderate (n=8,8,8,8,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Itching: none (n=8,8,7,7,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Bruising: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Bruising: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: none (n=8,8,8,8,8)	6 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Bruising: mild (n=8,8,8,7,8)	1 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Swelling: severe (n=8,8,8,8,8)	1 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Redness: moderate (n=8,8,8,8,8)	1 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Itching: none (n=8,8,8,9,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Indurations: none (n=8,8,8,8,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Redness: none (n=8,8,8,8,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Redness: moderate (n=8,8,7,7,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Itching: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: mild (n=8,8,8,8,8)	2 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Swelling: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Redness: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Itching: none (8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Redness: none (n=8,8,8,9,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Redness: none (n=8,8,8,9,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Itching: none (n=7,8,7,6,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Indurations: none (n=8,8,7,7,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Indurations: none (n=8,8,7,7,7)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Swelling: none (n=8,8,8,9,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Indurations: none (n=8,8,7,7,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Bruising: mild (n=7,8,7,7,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Bruising: none (n=8,8,8,7,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Bruising: none (n=8,8,8,9,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Swelling: none (n=8,8,7,7,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Bruising: none (n=7,8,7,7,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Swelling: none (n=8,8,8,8,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Redness: severe (n=8,8,8,8,8)	1 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Swelling: none (n=8,8,8,9,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Indurations: severe (n=8,8,8,8,8)	1 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Itching: none (n=8,8,8,9,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Swelling: mild (n=8,8,8,7,8)	1 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Redness: none (n==8,8,7,7,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Itching: none (n=8,8,8,7,8)	8 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Swelling: mild (n=8,8,8,8,8)	1 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: none (n=8,8,8,8,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Redness: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Bruising: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Swelling: none (n=8,8,8,8,8)	7 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Redness: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 120 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Bruising: none (n=8,8,8,7,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Redness: mild (n=8,8,8,9,8)	1 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Swelling: none (n=8,8,8,9,8)	9 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Indurations: none (n=8,8,7,7,8)	7 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Swelling: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Bruising: none (n=8,8,8,9,8)	9 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Bruising: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Bruising: mild (n=8,8,8,7,8)	1 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Indurations: none (n=8,8,8,9,8)	9 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Itching: none (n=8,8,8,9,8)	9 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Redness: none (n=8,8,8,9,8)	9 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Bruising: none (n=8,8,8,7,8)	6 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Swelling: none (n=8,8,8,9,8)	9 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Bruising: none (n=8,8,8,7,8)	7 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Swelling: mild (n=8,8,8,7,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Indurations: severe (n=8,8,8,8,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Redness: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Swelling: none (n=8,8,8,7,8)	7 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: moderate (n=8,8,8,8,8)	1 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Bruising: none (n=8,8,8,8,8)	7 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Bruising: mild (n=8,8,8,8,8)	1 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: mild (n=8,8,8,8,8)	2 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Itching: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Itching: none (8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Itching: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Redness: moderate (n=8,8,8,8,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: none (n=8,8,8,8,8)	5 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Indurations: none (n=8,8,8,9,8)	9 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Bruising: none (n=8,8,8,9,8)	9 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Indurations: mild (n=8,8,8,9,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Itching: none (n=8,8,8,7,8)	7 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Redness: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Swelling: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Swelling: mild (n=8,8,8,8,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Swelling: severe (n=8,8,8,8,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Swelling: none (n=8,8,7,7,8)	7 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Bruising: none (n=7,8,7,7,8)	6 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Bruising: none (n=8,8,8,8,8)	7 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Bruising: mild (n=7,8,7,7,8)	1 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Indurations: none (n=8,8,7,7,7)	7 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Redness: moderate (n=8,8,7,7,8)	1 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Indurations: none (n=8,8,7,7,8)	7 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Itching: none (n=7,8,7,6,8)	6 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Redness: severe (n=8,8,8,8,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Bruising: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Indurations: none (n=8,8,8,8,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Redness: none (n==8,8,7,7,8)	6 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Bruising: mild (n=8,8,8,8,8)	1 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: moderate (n=8,8,8,8,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Itching: none (n=8,8,8,9,8)	8 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Itching: mild (n=8,8,8,9,8)	1 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Itching: none (n=8,8,7,7,8)	0 subjects
MSB0010841 240 mg	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Redness: none (n=8,8,8,9,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Redness: mild (n=8,8,8,9,8)	2 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Redness: mild (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: mild (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Redness: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Itching: mild (n=8,8,8,9,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Swelling: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Indurations: severe (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Swelling: severe (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Swelling: none (n=8,8,8,7,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Redness: none (n=8,8,8,9,8)	6 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Swelling: mild (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Redness: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Bruising: mild (n=8,8,8,9,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Itching: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Indurations: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Itching: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Redness: severe (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Bruising: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Swelling: none (n=8,8,7,7,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: moderate (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Indurations: none (n=8,8,7,7,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Swelling: mild (n=8,8,8,7,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Indurations: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Bruising: none (n=7,8,7,7,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Bruising: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Bruising: mild (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Swelling: none (n=8,8,8,9,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Bruising: mild (n=8,8,8,7,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Bruising: mild (n=7,8,7,7,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Redness: moderate (n=8,8,7,7,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Bruising: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Indurations: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Bruising: none (n=8,8,8,9,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Indurations: none (n=8,8,7,7,7)	7 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Indurations: none (n=8,8,7,7,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Itching: none (n=8,8,8,9,8)	9 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Swelling: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Redness: none (n=8,8,8,9,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Itching: none (8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Redness: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Itching: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Redness: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Itching: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Itching: none (n=8,8,7,7,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: mild (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 36 Itching: none (n=7,8,7,6,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Redness: moderate (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Bruising: none (n=8,8,8,7,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 22 Itching: mild (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Indurations: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Swelling: mild (n=8,8,8,9,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Swelling: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Bruising: mild (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 16 Bruising: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Itching: none (n=8,8,8,9,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Indurations: none (n=8,8,8,9,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Itching: none (n=8,8,8,7,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Redness: moderate (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Swelling: none (n=8,8,8,9,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Swelling: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Bruising: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 43 Indurations: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 30 Redness: none (n==8,8,7,7,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Bruising: none (n=8,8,8,9,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 2 Indurations: none (n=8,8,8,9,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Swelling: none (n=8,8,8,8,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 29 Bruising: none (n=8,8,8,7,8)	8 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 8 Redness: mild (n=8,8,8,8,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 1 Indurations: mild (n=8,8,8,9,8)	0 subjects
Placebo	Number of Subjects With Local Injection Site Reactions (ISRs)	Day 15 Redness: none (n=8,8,8,8,8)	8 subjects

Primary

Number of Subjects With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. TEAEs were the AEs occurring or worsening after treatment administration.

Time frame: Baseline up to Day 85

Population: Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo).

Arm	Measure	Value (NUMBER)
MSB0010841 30 mg	Number of Subjects With Treatment Emergent Adverse Events (TEAEs)	6 subjects
MSB0010841 60 mg	Number of Subjects With Treatment Emergent Adverse Events (TEAEs)	5 subjects
MSB0010841 120 mg	Number of Subjects With Treatment Emergent Adverse Events (TEAEs)	5 subjects
MSB0010841 240 mg	Number of Subjects With Treatment Emergent Adverse Events (TEAEs)	6 subjects
Placebo	Number of Subjects With Treatment Emergent Adverse Events (TEAEs)	6 subjects

Primary

Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841

The observed serum concentration immediately before the first dose.

Time frame: Pre-dose (0 hours) on Day 1

Arm	Measure	Value (MEAN)	Dispersion
MSB0010841 30 mg	Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841	0.01 mcg/mL	Standard Deviation 0.036
MSB0010841 60 mg	Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841	0.00 mcg/mL	Standard Deviation 0
MSB0010841 120 mg	Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841	0.00 mcg/mL	Standard Deviation 0
MSB0010841 240 mg	Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841	0.00 mcg/mL	Standard Deviation 0

Primary

Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841

The observed serum concentration immediately before second dose.

Time frame: Pre-dose (0 hours) on Day 15

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841	1.65 mcg/mL	Geometric Coefficient of Variation 30.2
MSB0010841 60 mg	Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841	3.74 mcg/mL	Geometric Coefficient of Variation 37.9
MSB0010841 120 mg	Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841	6.34 mcg/mL	Geometric Coefficient of Variation 38.3
MSB0010841 240 mg	Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841	11.44 mcg/mL	Geometric Coefficient of Variation 18.1

Primary

Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841

The observed serum concentration immediately before the third dose.

Time frame: Pre-dose (0 hours) on Day 29

Arm	Measure	Value (MEAN)	Dispersion
MSB0010841 30 mg	Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841	2.31 mcg/mL	Standard Deviation 0.59
MSB0010841 60 mg	Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841	4.49 mcg/mL	Standard Deviation 1.4
MSB0010841 120 mg	Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841	10.42 mcg/mL	Standard Deviation 4.72
MSB0010841 240 mg	Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841	16.17 mcg/mL	Standard Deviation 4.84

Primary

Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])

Data were presented for MSB0010841 combined group and placebo.

Time frame: Baseline up to Day 85

Population: Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo).

Arm	Measure	Value (NUMBER)
MSB0010841 30 mg	Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])	30.3 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])	37.5 percentage of subjects

Primary

Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841

The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

Population: PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here Number of subjects analyzed signifies those subjects who were evaluable for this outcome measure.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841	140.28 percentage fluctuation	Geometric Coefficient of Variation 3.9
MSB0010841 60 mg	Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841	152.47 percentage fluctuation	Geometric Coefficient of Variation 20.4
MSB0010841 120 mg	Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841	144.37 percentage fluctuation	Geometric Coefficient of Variation 13
MSB0010841 240 mg	Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841	135.89 percentage fluctuation	Geometric Coefficient of Variation 12.3

Primary

Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841

The peak trough fluctuation within one dosing interval, calculated as PTF (%) = (\[Cmax - Cmin\]/Cav ) multiplied by 100

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Population: PK analysis set included subjects who received active treatment (MSB0010841) without protocol deviations affecting PK, and who provide evaluable PK data. Here Number of subjects analyzed signifies those subjects who were evaluable for this outcome measure.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
MSB0010841 30 mg	Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841	75.26 percentage fluctuation	Geometric Coefficient of Variation 8.5
MSB0010841 60 mg	Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841	95.65 percentage fluctuation	Geometric Coefficient of Variation 18.9
MSB0010841 120 mg	Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841	71.17 percentage fluctuation	Geometric Coefficient of Variation 33.1
MSB0010841 240 mg	Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841	76.03 percentage fluctuation	Geometric Coefficient of Variation 28.6

Primary

Terminal Rate Constant (λz) Post Third Dose of MSB0010841

Terminal rate constant was determined from the terminal slope of the logtransformed concentration curve using linear regression on terminal data points of the curve

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Arm	Measure	Dispersion
MSB0010841 30 mg	Terminal Rate Constant (λz) Post Third Dose of MSB0010841	Geometric Coefficient of Variation 17.3
MSB0010841 60 mg	Terminal Rate Constant (λz) Post Third Dose of MSB0010841	Geometric Coefficient of Variation 18.9
MSB0010841 120 mg	Terminal Rate Constant (λz) Post Third Dose of MSB0010841	Geometric Coefficient of Variation 27.9
MSB0010841 240 mg	Terminal Rate Constant (λz) Post Third Dose of MSB0010841	Geometric Coefficient of Variation 13.1

Primary

Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841

Time frame: 0 hours (pre-dose), 24, 72, 96, 168, 336 hours post-second dose (Day 15)

Arm	Measure	Value (MEDIAN)
MSB0010841 30 mg	Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841	84.2 hour
MSB0010841 60 mg	Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841	72.0 hour
MSB0010841 120 mg	Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841	83.4 hour
MSB0010841 240 mg	Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841	72.0 hour

Primary

Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336 hours post-first dose (Day 1)

Arm	Measure	Value (MEDIAN)
MSB0010841 30 mg	Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841	72.39 hour
MSB0010841 60 mg	Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841	71.68 hour
MSB0010841 120 mg	Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841	52.00 hour
MSB0010841 240 mg	Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841	72.23 hour

Primary

Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841

Time frame: 0 hours (pre-dose), 6, 12, 24, 32, 72, 96, 168, 336, 504, 816, 1056, 1344 hours post-third dose (Day 29)

Arm	Measure	Value (MEDIAN)
MSB0010841 30 mg	Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841	31.5 hour
MSB0010841 60 mg	Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841	31.0 hour
MSB0010841 120 mg	Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841	72.0 hour
MSB0010841 240 mg	Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841	72.0 hour

Secondary

Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43

PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of subjects who achieved \>=50 or 75% improvement in PASI score from Baseline.

Time frame: Baseline, Day 43

Population: Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo).

Arm	Measure	Group	Value (MEAN)	Dispersion
MSB0010841 30 mg	Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43	Baseline	16.91 units on a scale	Standard Deviation 5.75
MSB0010841 30 mg	Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43	Change at Day 43	-13.93 units on a scale	Standard Deviation 4.76
MSB0010841 60 mg	Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43	Baseline	19.76 units on a scale	Standard Deviation 4.79
MSB0010841 60 mg	Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43	Change at Day 43	-17.99 units on a scale	Standard Deviation 5.52
MSB0010841 120 mg	Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43	Baseline	23.35 units on a scale	Standard Deviation 6.6
MSB0010841 120 mg	Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43	Change at Day 43	-21.70 units on a scale	Standard Deviation 8.52
MSB0010841 240 mg	Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43	Change at Day 43	-16.68 units on a scale	Standard Deviation 8.38
MSB0010841 240 mg	Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43	Baseline	18.38 units on a scale	Standard Deviation 6.07
Placebo	Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43	Baseline	25.49 units on a scale	Standard Deviation 5.58
Placebo	Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43	Change at Day 43	-5.43 units on a scale	Standard Deviation 7.04

Secondary

Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85

The BSA is the physician's evaluation for the extent of disease. The entire body area is divided into 4 districts: head, upper limbs, trunk and lower limbs to which corresponds the 10%, 20%, 30% and 40% of the entire body surface respectively. The investigator assesses the percentage of the subjects' body surface area affected by psoriasis in each district. The final affected BSA value is the sum of the percentage of each district.

Time frame: Baseline, Day 8, 15, 22, 29, 36, 43, 50 and 85

Population: Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo). Here n signifies those subjects who were evaluable for this outcome measure at the specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
MSB0010841 30 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 43 (8,8,8,9,8)	-52.6 percent change	Standard Deviation 32.91
MSB0010841 30 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 22 (n=8,8,8,8,8)	-11.6 percent change	Standard Deviation 24.9
MSB0010841 30 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 8 (n=8,8,8,8,8)	0.4 percent change	Standard Deviation 1.14
MSB0010841 30 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 85 (8,8,8,9,8)	-60.4 percent change	Standard Deviation 33.51
MSB0010841 30 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 36 (8,8,7,7,7)	-31.4 percent change	Standard Deviation 22.96
MSB0010841 30 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 29 (n=8,8,8,8,8)	-22.6 percent change	Standard Deviation 26.35
MSB0010841 30 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 50 (n=8,8,8,9,8)	-56.2 percent change	Standard Deviation 34.71
MSB0010841 30 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 15 (n=8,8,8,8,8)	0.4 percent change	Standard Deviation 1.14
MSB0010841 60 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 36 (8,8,7,7,7)	-52.7 percent change	Standard Deviation 37.57
MSB0010841 60 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 43 (8,8,8,9,8)	-65.2 percent change	Standard Deviation 28.61
MSB0010841 60 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 85 (8,8,8,9,8)	-61.3 percent change	Standard Deviation 33.89
MSB0010841 60 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 15 (n=8,8,8,8,8)	-33.1 percent change	Standard Deviation 35.97
MSB0010841 60 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 22 (n=8,8,8,8,8)	-40.2 percent change	Standard Deviation 40.68
MSB0010841 60 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 8 (n=8,8,8,8,8)	-30.0 percent change	Standard Deviation 31.23
MSB0010841 60 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 29 (n=8,8,8,8,8)	-44.1 percent change	Standard Deviation 42.53
MSB0010841 60 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 50 (n=8,8,8,9,8)	-69.4 percent change	Standard Deviation 25.85
MSB0010841 120 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 50 (n=8,8,8,9,8)	-79.1 percent change	Standard Deviation 32.3
MSB0010841 120 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 43 (8,8,8,9,8)	-75.4 percent change	Standard Deviation 37.35
MSB0010841 120 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 85 (8,8,8,9,8)	-82.1 percent change	Standard Deviation 31.05
MSB0010841 120 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 29 (n=8,8,8,8,8)	-55.9 percent change	Standard Deviation 36.56
MSB0010841 120 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 15 (n=8,8,8,8,8)	-20.5 percent change	Standard Deviation 10.98
MSB0010841 120 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 8 (n=8,8,8,8,8)	-13.7 percent change	Standard Deviation 15.13
MSB0010841 120 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 22 (n=8,8,8,8,8)	-42.6 percent change	Standard Deviation 27.15
MSB0010841 120 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 36 (8,8,7,7,7)	-64.6 percent change	Standard Deviation 37.65
MSB0010841 240 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 50 (n=8,8,8,9,8)	-82.2 percent change	Standard Deviation 36.64
MSB0010841 240 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 8 (n=8,8,8,8,8)	-12.5 percent change	Standard Deviation 23.81
MSB0010841 240 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 15 (n=8,8,8,8,8)	-51.1 percent change	Standard Deviation 43.17
MSB0010841 240 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 22 (n=8,8,8,8,8)	-68.5 percent change	Standard Deviation 38.71
MSB0010841 240 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 29 (n=8,8,8,8,8)	-82.9 percent change	Standard Deviation 34.46
MSB0010841 240 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 36 (8,8,7,7,7)	-83.5 percent change	Standard Deviation 31.6
MSB0010841 240 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 43 (8,8,8,9,8)	-82.2 percent change	Standard Deviation 36.64
MSB0010841 240 mg	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 85 (8,8,8,9,8)	-95.5 percent change	Standard Deviation 11.02
Placebo	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 36 (8,8,7,7,7)	-0.5 percent change	Standard Deviation 27.92
Placebo	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 29 (n=8,8,8,8,8)	-0.1 percent change	Standard Deviation 26.13
Placebo	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 22 (n=8,8,8,8,8)	-5.1 percent change	Standard Deviation 12.69
Placebo	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 15 (n=8,8,8,8,8)	-4.2 percent change	Standard Deviation 12.21
Placebo	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 8 (n=8,8,8,8,8)	2.9 percent change	Standard Deviation 23.32
Placebo	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 50 (n=8,8,8,9,8)	-10.0 percent change	Standard Deviation 17.87
Placebo	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 85 (8,8,8,9,8)	-13.0 percent change	Standard Deviation 20.13
Placebo	Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85	Change at Day 43 (8,8,8,9,8)	-1.5 percent change	Standard Deviation 27.05

Secondary

Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score

PASI: a physician assessed index that measured psoriasis severity and evaluated erythema, infiltration, and desquamation (scaling) on different body areas including the head, upper extremities, the trunk, and lower extremities. T Erythema, infiltration, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. These values for each anatomic region are summed to yield the PASI score. PASI score ranged from 0 to 72, with higher scores reflecting greater disease severity. PASI 50% or 75% was defined as the percentage of participants who achieved \>=50 or 75% improvement in PASI score from Baseline.

Time frame: Baseline up to Day 85

Population: Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo).

Arm	Measure	Group	Value (NUMBER)
MSB0010841 30 mg	Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score	PASI-50	100 percentage of subjects
MSB0010841 30 mg	Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score	PASI-75	88 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score	PASI-75	100 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score	PASI-50	100 percentage of subjects
MSB0010841 120 mg	Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score	PASI-75	100 percentage of subjects
MSB0010841 120 mg	Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score	PASI-50	100 percentage of subjects
MSB0010841 240 mg	Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score	PASI-50	100 percentage of subjects
MSB0010841 240 mg	Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score	PASI-75	100 percentage of subjects
Placebo	Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score	PASI-75	0 percentage of subjects
Placebo	Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score	PASI-50	50 percentage of subjects

Secondary

Percentage of Subjects With Exacerbation of Psoriasis

Psoriasis exacerbation was defined as either a worsening of 25% over the baseline value of the PASI score (PASI score at any visit \>=125% of baseline PASI).

Time frame: Baseline up to Day 85

Population: Safety analysis set included all 41 subjects who received at least 1 dose of IMP (MSB0010841 or placebo).

Arm	Measure	Value (NUMBER)
MSB0010841 30 mg	Percentage of Subjects With Exacerbation of Psoriasis	0 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With Exacerbation of Psoriasis	0 percentage of subjects
MSB0010841 120 mg	Percentage of Subjects With Exacerbation of Psoriasis	0 percentage of subjects
MSB0010841 240 mg	Percentage of Subjects With Exacerbation of Psoriasis	0 percentage of subjects
Placebo	Percentage of Subjects With Exacerbation of Psoriasis	12.5 percentage of subjects

Secondary

Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline

The static Physician's Global Assessment (sPGA) scale rated the investigator's overall clinical assessment of a subjects plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale). To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling. Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score. Overall sPGA score ranged from 0 to 5, where lower scores indicate clinical improvement. Percentage of subjects who achieved a sPGA rating of 0 (clear) or 1 (minimal) and had at Least 2 level reduction from Baseline score were reported.

Time frame: Day 8, 15, 22, 29, 36, 43, 50, 85

Population: Safety analysis set included all 41 subjects who received at least one dose of IMP (MSB0010841 or placebo).

Arm	Measure	Group	Value (NUMBER)
MSB0010841 30 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 15	25 percentage of subjects
MSB0010841 30 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 8	0 percentage of subjects
MSB0010841 30 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 22	50 percentage of subjects
MSB0010841 30 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 85	88 percentage of subjects
MSB0010841 30 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 50	75 percentage of subjects
MSB0010841 30 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 36	63 percentage of subjects
MSB0010841 30 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 29	63 percentage of subjects
MSB0010841 30 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 43	75 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 50	88 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 85	88 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 15	25 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 22	50 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 29	63 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 36	88 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 43	88 percentage of subjects
MSB0010841 60 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 8	38 percentage of subjects
MSB0010841 120 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 36	75 percentage of subjects
MSB0010841 120 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 43	75 percentage of subjects
MSB0010841 120 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 8	13 percentage of subjects
MSB0010841 120 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 29	88 percentage of subjects
MSB0010841 120 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 22	50 percentage of subjects
MSB0010841 120 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 15	13 percentage of subjects
MSB0010841 120 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 85	88 percentage of subjects
MSB0010841 120 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 50	100 percentage of subjects
MSB0010841 240 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 22	67 percentage of subjects
MSB0010841 240 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 85	100 percentage of subjects
MSB0010841 240 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 29	78 percentage of subjects
MSB0010841 240 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 43	67 percentage of subjects
MSB0010841 240 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 36	67 percentage of subjects
MSB0010841 240 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 15	56 percentage of subjects
MSB0010841 240 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 50	89 percentage of subjects
MSB0010841 240 mg	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 8	11 percentage of subjects
Placebo	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 85	0 percentage of subjects
Placebo	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 15	0 percentage of subjects
Placebo	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 22	0 percentage of subjects
Placebo	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 29	0 percentage of subjects
Placebo	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 36	0 percentage of subjects
Placebo	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 43	0 percentage of subjects
Placebo	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 50	0 percentage of subjects
Placebo	Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline	Day 8	0 percentage of subjects

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Accumulation Ratio of AUC (Racc(AUC))

Accumulation Ratio of Cmax (Racc (Cmax))

Amount of Pain at Injection Site Assessed By Visual Analog Scale (VAS)

Apparent Clearance (CL/f) Post Third Dose of MSB0010841

Apparent Terminal Half-life (t1/2) Post Third Dose of MSB0010841

Apparent Volume of Distribution During Terminal Phase (Vz/f) Post Third Dose of MSB0010841

Area Under the Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) Post Third Dose of MSB0010841

Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post First Dose of MSB0010841

Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) Post Third Dose of MSB0010841

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post First Dose of MSB0010841

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) Post Third Dose of MSB0010841

Average Concentration (Cav) Post First Dose of MSB0010841

Average Concentration (Cav) Post Third Dose of MSB0010841

Levels of Anti-MSB0010841 Antibody Titers

Levels of Pre-existing Anti-MSB0010841 Antibody Titers

Maximum Concentration Observed (Cmax) Post First Dose of MSB0010841

Maximum Concentration Observed (Cmax) Post Third Dose of MSB0010841

Maximum Observed Concentration (Cmax) Post Second Dose of MSB0010841

Mean Residence Time (MRT0-t) Post First Dose of MSB0010841

Mean Residence Time (MRT0-t) Post Third Dose of MSB0010841

Mean Residence Time of Drug in the Body From Time Zero Extrapolated to Infinity (MRT(0-inf) Post Third Dose of MSB0010841

Minimum Concentration Observed (Cmin) During First Dosing Interval of MSB0010841

Minimum Concentration Observed (Cmin) During Third Dosing Interval of MSB0010841

MSB0010841 Serum Concentration Over Time After First Dose

MSB0010841 Serum Concentration Over Time After Second Dose

MSB0010841 Serum Concentration Over Time After Third Dose

Number of Subjects With Local Injection Site Reactions (ISRs)

Number of Subjects With Treatment Emergent Adverse Events (TEAEs)

Observed Serum Concentration Immediately Before First Dose (Cpre) of MSB0010841

Observed Serum Concentration Immediately Before Second Dose (Cpre) of MSB0010841

Observed Serum Concentration Immediately Before Third Dose (Cpre) of MSB0010841

Percentage of Subjects With Anti-MSB0010841 Binding Antibodies (Anti-Drug Antibodies [ADA])

Percentage Peak-Trough Fluctuation (PTF) Post First Dose of MSB0010841

Percentage Peak-Trough Fluctuation (PTF) Post Third Dose of MSB0010841

Terminal Rate Constant (λz) Post Third Dose of MSB0010841

Time to Maximum Observed Concentration (Tmax) Post Second Dose of MSB0010841

Time to Reach Maximum Observed Concentration (Tmax) Post First Dose of MSB0010841

Time to Reach Maximum Observed Concentration (Tmax) Post Third Dose of MSB0010841

Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 43

Mean Percent Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Day 8, 15, 22, 29, 36, 43, 50 and 85

Percentage of Subjects With 50% or 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score

Percentage of Subjects With Exacerbation of Psoriasis

Percentage of Subjects With Static Physician's Global Assessment (sPGA) Score of Minimal or Clear and With at Least 2 Level Reduction From Baseline